(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
How Deforestation Is Reshaping Mosquito-Human Contact - 275% of US adults may meet criteria for obesity under new definition, study finds
- 3Manual for 10 Scrumptious Specialty Mixed drinks
- 4Flourishing as a Charitable Pioneer: Individual Encounters in Generosity
- 5Former defense minister Gallant vacated home over security threat under Shin Bet direction
- Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
- Lucky airplane passengers capture NASA's Artemis 2 moon launch from the sky
- Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- 6 Tire Brands Reasonable for Seniors
- Internet goes (cocoa) nuts: The funniest reactions to 12 tonne theft of KitKat bars
- Fundamental Home Exercise center Hardware: Amplify Your Exercises
- Islamabad: Iran allows 20 Pakistani ships through Strait of Hormuz
- Nutrient Rich Organic products: Lift Your Wellbeing
- The most effective method to Look at Medical caretaker Compensations Across Various Clinics
